A coronavirus vaccine trial resumed Saturday in the United Kingdom after the study was paused for a week because of an unexplained illness in a trial participant.

The recommendation to resume human testing of the vaccine candidate being developed by the University of Oxford and pharmaceutical giant AstraZeneca was made by an independent safety review committee and by the U.K. health regulator. Authorities made no further information available about the nature of the participant’s illness, citing privacy protections.

“Globally some 18,000 individuals have received study vaccines as part of the trial. In large trials such as this, it is expected that some participants will become unwell and every case must be carefully evaluated to ensure careful assessment of safety,” the University of Oxford said in a statement.

AstraZeneca released a statement that it was working with global health authorities to “be guided as to when other clinical trials can resume,” including the 30,000-person trial in the United States that began in late August.

The temporary hold on the trial because of a single illness was seen by many experts as evidence that systems in place to protect patient safety are functioning properly….